Anna Campanati
Overview
Explore the profile of Anna Campanati including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
168
Citations
1294
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Orsini D, Graceffa D, Burlando M, Campanati A, Campione E, Guarneri C, et al.
J Clin Med
. 2025 Feb;
14(4).
PMID: 40004618
: Brodalumab is a monoclonal antibody against the anti-IL-17 receptor A, approved for patients with moderate-to-severe psoriasis. This retrospective study investigated patients in clinical practice to assess the impact of...
2.
Di Vincenzo M, Pellegrino P, Schiappa G, Campanati A, Del Vescovo V, Piccirillo S, et al.
Int J Mol Sci
. 2025 Feb;
26(3).
PMID: 39941125
The role of 11β-HSD1 in Alzheimer's disease (AD) has garnered significant attention due to its involvement in glucocorticoid metabolism, neuroinflammation, and cognitive decline. This review explores the current understanding of...
3.
Barei F, Calzari P, Pezzolo E, Napolitano M, Rossi M, Guanti M, et al.
Clin Exp Dermatol
. 2025 Feb;
PMID: 39899459
Background: Tralokinumab has demonstrated efficacy in the treatment atopic dermatitis (AD) in both clinical trials and real-world settings. However, limited data exists on the long-term use of tralokinumab in real-world...
4.
Diotallevi F, Esposito M, Fargnoli M, Quaglino P, Mastorino L, Stingeni L, et al.
Dermatol Ther (Heidelb)
. 2025 Jan;
15(2):323-336.
PMID: 39847259
Introduction: Palmoplantar psoriasis (PPp) has a profound negative impact on patients' quality of life, and it represents a therapeutic challenge, as palms and soles are difficult to treat area. Although...
5.
Diotallevi F, Matacchione G, Campanati A, Marinelli Busilacchi E, Viola N, Pace I, et al.
Dermatol Ther (Heidelb)
. 2025 Jan;
15(1):125-140.
PMID: 39800831
Introduction: Psoriasis is characterized by aberrant keratinocyte activity and immune cell infiltration, driven by immune-mediated pathways. MicroRNAs (miRNAs) play crucial roles in regulating these processes, offering insights into disease mechanisms...
6.
Campione E, Artosi F, Shumak R, Giunta A, Argenziano G, Assorgi C, et al.
Pharmaceuticals (Basel)
. 2024 Oct;
17(10).
PMID: 39459016
(1) Background/Objectives: Nail psoriasis (NP) is a chronic and difficult-to-treat disease, which causes significant social stigma and impairs the patients' quality of life. Moreover, nail psoriasis is a true therapeutic...
7.
Campanati A, Esposito M, Caldarola G, Cacciapuoti S, Fabbrocini G
Drugs Context
. 2024 Oct;
13.
PMID: 39416771
A fixed-dose combination of calcipotriene 0.005%/betamethasone dipropionate 0.064% (Cal/BD) aerosol foam (Enstilar, LEO Pharma) is the only topical therapy approved for the acute (reactive) and proactive management of psoriasis. Although...
8.
Megna M, Orsini D, Assorgi C, Balato A, Balestri R, Bianchi L, et al.
Clin Exp Dermatol
. 2024 Oct;
PMID: 39373543
No abstract available.
9.
Di Giuseppe J, Delli Carpini G, Giannella L, Terenzi T, Fichera M, Ragno F, et al.
J Low Genit Tract Dis
. 2024 Apr;
28(3):276-281.
PMID: 38661348
Objective: The main outcome of this study was the evaluation of clinical characteristics, comorbidities, and therapeutic approaches in patients with vulvar lichen sclerosus (VLS) aged from childhood to perimenopause. Secondly,...
10.
Orsini D, Malagoli P, Balato A, Bianchi L, Brianti P, Buononato D, et al.
Dermatol Pract Concept
. 2024 Feb;
14(2).
PMID: 38416060
Introduction: Genital involvement is observed in approximately 60% of patients with psoriasis, presenting clinicians with formidable challenges in treatment. While new biologic drugs have emerged as safe and effective options...